非对称性二甲基精氨酸与卒中

Asymmetric Dimethylarginine and Stroke

非对称性二甲基精氨酸（ADMA）是一氧化氮合酶（NOS）抑制剂。ADMA是通过左旋精氨酸残基甲基化形成的，可抑制血管活性物质NO的生成，导致内皮功能不全和血管性疾病。大量研究表明，ADMA可能是一种卒中危险因素。在高同型半胱氨酸血症、颈动脉狭窄和心血管疾病患者中，ADMA表达显著增高。

Asymmetric dimethylarginine （ADMA） is a nitric oxide synthase （NOS） inhibitor. ADMA is formed by methylation of L-arginine residues. It inhibits the formation of vasoactive substances （nitric oxide）, resulting in endothelial dysfunction and vascular diseases. A number of studies have suggested that ADMA may be a risk factor for stroke, The expression of ADMA increases significantly in patients with hyperhomocysteinemia, carotid stenosis and cardiow, scular disease.